Skip to main content
F

Fusen Pharmaceutical Company Limited — Investor Relations & Filings

Ticker · 1652 HKEX Manufacturing
Open in API
Filings indexed 446 across all filing types
Latest filing 2026-01-02 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 1652

About Fusen Pharmaceutical Company Limited

http://www.fusenyy.com

Fusen Pharmaceutical Company Limited operates as a comprehensive pharmaceutical enterprise, integrating the cultivation of Chinese herbal medicine, drug research and development (R&D), production, and sales. The company manufactures and markets a diverse range of pharmaceutical products, including tablets, capsules, and oral solutions. Its therapeutic focus spans critical areas such as respiratory tract conditions, antiviral infections, cardio cerebrovascular diseases, digestion, and metabolism. Fusen is known for providing cold remedies, particularly those based on Shuanghuanglian, and actively develops and markets prescription drugs, demonstrating a commitment to both traditional and modern pharmaceutical solutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Earnings Release', but rather serves as a recurring regulatory disclosure. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-02 English
VOLUNTARY ANNOUNCEMENT "COMPOUND POTASSIUM HYDROGEN PHOSPHATE INJECTION" APPROVED FOR MARKETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Fusen Pharmaceutical Company Limited regarding the regulatory approval of a new drug, 'Compound Potassium Hydrogen Phosphate Injection'. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. Since it is a general regulatory announcement regarding business operations and product development that does not fall into specific categories like M&A or dividends, it is classified as a general regulatory filing.
2025-12-29 English
CHANGE OF AUDITOR
Regulatory Filings Classification · 1% confidence The document is an official announcement regarding the resignation of the current auditor (KPMG) and the appointment of a new auditor (CCTH CPA Limited) for Fusen Pharmaceutical Company Limited. This type of corporate governance disclosure, specifically concerning the change of key service providers like auditors, falls under the category of general regulatory announcements or governance-related filings. Since there is no specific category for 'Change of Auditor' and it does not fit into Board/Management changes (which refers to Directors/Executives), it is best classified as a Regulatory Filing (RNS).
2025-12-24 English
VOLUNTARY ANNOUNCEMENT NOTIFICATION OF APPROVAL OF CONSISTENCY EVALUATION OF "NICARDIPINE HYDROCHLORIDE INJECTION"
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Fusen Pharmaceutical Company Limited regarding the regulatory approval of a specific drug product ('Nicardipine Hydrochloride Injection'). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general regulatory announcement regarding company operations and product approvals that does not fall into specific categories like M&A or dividends, it is best classified as a general regulatory filing.
2025-12-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which implies a specific event) or 'Director's Dealing', it is best classified as a general regulatory filing.
2025-12-01 English
VOLUNTARY ANNOUNCEMENT "MEASARTAN POTASSIUM TABLETS" APPROVED FOR MARKETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Fusen Pharmaceutical Company Limited regarding the regulatory approval of a new drug ('Measartan Potassium Tablets') for marketing. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it provides substantive news about product development rather than just announcing the availability of a report. As it is a general corporate regulatory announcement that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.